Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hospices Civils de Lyon | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease.
In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MS Patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood sample | Diagnostic Test | 2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels |
|
| Measure | Description | Time Frame |
|---|---|---|
| Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease | pg/mL; measured by digital ELISA | Inclusion |
| GFAP level in patients with evolving disease compared to those with stable disease | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease | pg/mL; measured by digital ELISA | 6 months |
| GFAP level in patients with evolving disease compared to those with stable disease | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease | pg/mL; measured by digital ELISA | 12 months |
| GFAP level in patients with evolving disease compared to those with stable disease | pg/mL; measured by digital ELISA | 12 months |
| Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease | pg/mL; measured by digital ELISA | 18 months |
| GFAP level in patients with evolving disease compared to those with stable disease |
| Measure | Description | Time Frame |
|---|---|---|
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | Inclusion |
| GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. |
Not provided
Inclusion Criteria:
The patient has been correctly informed.
The patient must have given their informed and signed consent.
The patient must be insured or beneficiary of a health insurance plan.
The patient is at least (≥)15 years old.
The patient has MS according to diagnosis criteria (Thompson et al. 2017) and:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study population is composed of consecutive patients over 15 years of age, of both sexes, recruited during consultations for a CIS, RRMS or progressive MS at the Neurology department of 30 OFSEP centres and of Nîmes and Nantes University Hospitals. The patients recruited will have an EDSS score comprised between 0 - 7.0.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Eric Thouvenot | Contact | +33.(0)4.66.68.32.61 | eric.thouvenot@chu-nimes.fr |
| Name | Affiliation | Role |
|---|---|---|
| Eric Thouvenot | CHU Nimes | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU d'Amiens | Not yet recruiting | Amiens | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples
pg/mL; measured by digital ELISA |
| 18 months |
| Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease | pg/mL; measured by digital ELISA | 2 years |
| GFAP level in patients with evolving disease compared to those with stable disease | pg/mL; measured by digital ELISA | 3 years |
| GFAP level in patients with evolving disease compared to those with stable disease | pg/mL; measured by digital ELISA | 4 years |
| GFAP level in patients with evolving disease compared to those with stable disease | pg/mL; measured by digital ELISA | 5 years |
| GFAP level in patients with evolving disease compared to those with stable disease | pg/mL; measured by digital ELISA | 6 years |
pg/mL; measured by digital ELISA |
| Inclusion |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | 6 months |
| GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | 3 year |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | 4 year |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | 5 year |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | 6 year |
| GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | 18 months |
| GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | 2 years |
| GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients. | pg/mL; measured by digital ELISA | 2 years |
| Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients | pg/mL; measured by digital ELISA | Inclusion |
| GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients | pg/mL; measured by digital ELISA | 6 months |
| GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients | pg/mL; measured by digital ELISA | 1 year |
| GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients | pg/mL; measured by digital ELISA | 18 months |
| GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients | pg/mL; measured by digital ELISA | 2 years |
| GFAP level in patients with relapse compared to stable patients | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with relapse compared to stable patients | pg/mL; measured by digital ELISA | 6 months |
| GFAP level in patients with relapse compared to stable patients | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with relapse compared to stable patients | pg/mL; measured by digital ELISA | 1 year |
| GFAP level in patients with relapse compared to stable patients | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with relapse compared to stable patients | pg/mL; measured by digital ELISA | 18 months |
| GFAP level in patients with relapse compared to stable patients | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with relapse compared to stable patients | pg/mL; measured by digital ELISA | 2 years |
| GFAP level in patients with relapse compared to stable patients | pg/mL; measured by digital ELISA | 2 years |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients | pg/mL; measured by digital ELISA | Inclusion |
| GFAP level in patients with isolated MRI activity compared to stable patients | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients | pg/mL; measured by digital ELISA | 6 months |
| GFAP level in patients with isolated MRI activity compared to stable patients | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients | pg/mL; measured by digital ELISA | 1 year |
| Serum GFAP level in patients with isolated MRI activity compared to stable patients | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients | pg/mL; measured by digital ELISA | 18 months |
| Serum GFAP level in patients with isolated MRI activity compared to stable patients | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients | pg/mL; measured by digital ELISA | 2 years |
| Serum GFAP level in patients with isolated MRI activity compared to stable patients | pg/mL; measured by digital ELISA | 2 years |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | Inclusion |
| Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 6 months |
| Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 1 year |
| Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 18 months |
| Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 2 year |
| Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 2 year |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | Inclusion |
| Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 6 months |
| Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 1 year |
| Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 18 months |
| Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 2 years |
| Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients | pg/mL; measured by digital ELISA | 2 years |
| Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort | pg/mL; measured by digital ELISA | Inclusion |
| Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort | pg/mL; measured by digital ELISA | 6 months |
| Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort | pg/mL; measured by digital ELISA | 1 year |
| Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort | pg/mL; measured by digital ELISA | 18 months |
| Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort | pg/mL; measured by digital ELISA | 2 years |
| Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort | pg/mL; measured by digital ELISA | 2 years |
| Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease | pg/mL; measured by digital ELISA | Inclusion |
| Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease | pg/mL; measured by digital ELISA | 6 months |
| Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease | pg/mL; measured by digital ELISA | 1 year |
| Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease | pg/mL; measured by digital ELISA | 18 months |
| Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease | pg/mL; measured by digital ELISA | 2 years |
| Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease | pg/mL; measured by digital ELISA | 2 years |
| Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity) | pg/mL; measured by digital ELISA | Inclusion |
| Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity) | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity) | pg/mL; measured by digital ELISA | 6 months |
| Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity) | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity) | pg/mL; measured by digital ELISA | 1 year |
| Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity) | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity) | pg/mL; measured by digital ELISA | 18 months |
| Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity) | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity) | pg/mL; measured by digital ELISA | 2 years |
| Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity) | pg/mL; measured by digital ELISA | 2 years |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity) | pg/mL; measured by digital ELISA | Inclusion |
| Serum GFAP level in patients with disease activity (relapse or MRI activity) | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse, or MRI activity) | pg/mL; measured by digital ELISA | 6 months |
| Serum GFAP level in patients with disease activity (relapse, or MRI activity) | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity) | pg/mL; measured by digital ELISA | 1 year |
| Serum GFAP level in patients with disease activity (relapse or MRI activity) | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity) | pg/mL; measured by digital ELISA | 18 months |
| Serum GFAP level in patients with disease activity (relapse or MRI activity) | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity) | pg/mL; measured by digital ELISA | 2 years |
| Serum GFAP level in patients with disease activity (relapse or MRI activity) | pg/mL; measured by digital ELISA | 2 years |
| Serum Neurofilament Light Chain level in patients with relapses | pg/mL; measured by digital ELISA | Inclusion |
| Serum GFAP level in patients with relapses | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with relapses | pg/mL; measured by digital ELISA | 6 months |
| Serum GFAP level in patients with relapses | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with relapses | pg/mL; measured by digital ELISA | 1 year |
| Serum GFAP level in patients with relapses | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with relapses | pg/mL; measured by digital ELISA | 18 months |
| Serum GFAP level in patients with relapses | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with relapses | pg/mL; measured by digital ELISA | 2 years |
| Serum GFAP level in patients with relapses | pg/mL; measured by digital ELISA | 2 years |
| Serum Neurofilament Light Chain level in patients with MRI activity | pg/mL; measured by digital ELISA | Inclusion |
| Serum GFAP level in patients with MRI activity | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with MRI activity | pg/mL; measured by digital ELISA | 6 months |
| Serum GFAP level in patients with MRI activity | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with MRI activity | pg/mL; measured by digital ELISA | 1 year |
| Serum GFAP level in patients with MRI activity | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with MRI activity | pg/mL; measured by digital ELISA | 18 months |
| Serum GFAP level in patients with MRI activity | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with MRI activity | pg/mL; measured by digital ELISA | 2 years |
| Serum GFAP level in patients with MRI activity | pg/mL; measured by digital ELISA | 2 years |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement | pg/mL; measured by digital ELISA | Inclusion |
| Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement | pg/mL; measured by digital ELISA | 6 months |
| Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement | pg/mL; measured by digital ELISA | 1 year |
| Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement | pg/mL; measured by digital ELISA | 18 months |
| Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement | pg/mL; measured by digital ELISA | 2 years |
| Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement | pg/mL; measured by digital ELISA | 2 years |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement | pg/mL; measured by digital ELISA | Inclusion |
| Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement | pg/mL; measured by digital ELISA | 6 months |
| Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement | pg/mL; measured by digital ELISA | 6 months |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement | pg/mL; measured by digital ELISA | 1 year |
| Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement | pg/mL; measured by digital ELISA | 1 year |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement | pg/mL; measured by digital ELISA | 18 months |
| Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement | pg/mL; measured by digital ELISA | 18 months |
| Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement | pg/mL; measured by digital ELISA | 2 years |
| Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement | pg/mL; measured by digital ELISA | 2 years |
| Level of disability | Expanded Disability Status Scale (EDSS); scale 1= no disability to 10 = death from multiple sclerosis | Inclusion |
| Level of disability | Expanded Disability Status Scale (EDSS); scale 1= no disability to 10 = death from multiple sclerosis | Relapse (measured up to 2 years) |
| Severity of multiple sclerosis | Multiple Sclerosis Functional Composite | EDSS progression (measured up to 2 years) |
| Severity of multiple sclerosis | Multiple Sclerosis Functional Composite | Active MRI (measured up to 2 years) |
| Generic health status | EuroQol 5 dimension questionnaire (EQ-5D) | Inclusion |
| Generic health status | EuroQol 5 dimension questionnaire (EQ-5D) | Relapse (measured up to 2 years) |
| Generic health status | EuroQol 5 dimension questionnaire (EQ-5D) | EDSS progression (measured up to 2 years) |
| Generic health status | EuroQol 5 dimension questionnaire (EQ-5D) | active MRI (measured up to 2 years) |
| Use of Disease Modifying Drugs | Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies) | Inclusion |
| Use of Disease Modifying Drugs | Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies) | 6 monrths |
| Use of Disease Modifying Drugs | Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies) | 1 year |
| Use of Disease Modifying Drugs | Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies) | 18 months |
| Use of Disease Modifying Drugs | Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies) | 2 years |
| Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients | pg/mL; measured by digital ELISA | Inclusion |
| Serum GFAP in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients | pg/mL; measured by digital ELISA | Month 6 |
| Serum GFAP in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients | pg/mL; measured by digital ELISA | Month 6 |
| Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion | pg/mL; measured by digital ELISA | Inclusion |
| Serum GFAP in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion | pg/mL; measured by digital ELISA | Inclusion |
| Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion | pg/mL; measured by digital ELISA | Month 6 |
| Serum GFAP in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion | pg/mL; measured by digital ELISA | Month 6 |
| Create biobank | Blood samples | Inclusion |
| Create biobank | Blood samples | 6 months |
| Create biobank | Blood samples | 1 year |
| Create biobank | Blood samples | 18 months |
| Create biobank | Blood samples | 2 years |
| CHU de Besancon | Not yet recruiting | Besançon | France |
|
| CHU de Bordeaux | Not yet recruiting | Bordeaux | France |
|
| CHU de Caen | Not yet recruiting | Caen | France |
|
| CHU de Clermont Ferrand | Not yet recruiting | Clermont-Ferrand | France |
|
| Hopital Henri Mondor | Not yet recruiting | Créteil | France |
|
| CHU de Dijon | Not yet recruiting | Dijon | France |
|
| CHU de Grenoble | Not yet recruiting | Grenoble | France |
|
| CHU de Lille | Not yet recruiting | Lille | France |
|
| CHU de Limoges | Not yet recruiting | Limoges | France |
|
| CHU de Lyon | Not yet recruiting | Lyon | France |
|
| Hopital Timone | Not yet recruiting | Marseille | France |
|
| CHU de Montpellier | Not yet recruiting | Montpellier | France |
|
| CHU de Nancy | Not yet recruiting | Nancy | France |
|
| CHU de Nice | Not yet recruiting | Nice | France |
|
| CHU de Nimes | Recruiting | Nîmes | 30029 | France |
|
| Fondation Rothschild | Not yet recruiting | Paris | France |
|
| Hopital Pitie Salpetriere | Not yet recruiting | Paris | France |
|
| Hopital Saint Antoine | Not yet recruiting | Paris | France |
|
| CH de Poissy | Not yet recruiting | Poissy | France |
|
| CHU de Potiers | Not yet recruiting | Potiers | France |
|
| CHU de Rennes | Not yet recruiting | Rennes | France |
|
| CHU de Rouen | Not yet recruiting | Rouen | France |
|
| CHU de Saint Etienne | Not yet recruiting | Saint-Etienne | France |
|
| CHU de Strasbourg | Not yet recruiting | Strasbourg | France |
|
| CHU de Toulouse | Not yet recruiting | Toulouse | France |
|
| CHU de Tours | Not yet recruiting | Tours | France |
|
| CHU de Martinique | Not yet recruiting | Fort-de-France | Martinique |
|
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| C537987 | Charcot-Marie-Tooth disease, Type 1F |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |
Not provided
Not provided